Status:
COMPLETED
Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome
Lead Sponsor:
Yuzuncu Yil University
Conditions:
Overactive Bladder
Obstructive Sleep Apnea
Eligibility:
FEMALE
18-60 years
Phase:
PHASE4
Brief Summary
In this study, we aim to determine whether combined tolterodine and CPAP therapy is a more effective treatment for patients with OSAS than CPAP treatment only.
Eligibility Criteria
Inclusion
- Women older than 18 who underwent polysomnography test with suspicion of OSAS between 01.06.2020-01.01.2022 were enrolled in the study
- Patients with AHI ≥15 (moderate or severe) and OAB-V8≥8 were considered eligible for the study and randomized in two groups to receive either CPAP treatment only or CPAP treatment with tolterodine tartrate
Exclusion
- Patients diagnosed with neurological diseases, diabetes mellitus, congestive heart failure, infection, hematuria, urolithiasis, urinary tumors, and urinary retention were excluded from the study. Also, a history of lower urinary tract surgery and medication due to lower urinary tract symptoms were the exclusion criteria.
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05250245
Start Date
June 1 2020
End Date
January 1 2022
Last Update
February 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yuzuncu Yıl University
Van, Turkey (Türkiye)